Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study (Q36205344)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

O Fernández

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

C Oreja-Guevara

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

R Arroyo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

G Izquierdo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

J L Pérez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

1 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

259

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

1814-1823

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-012-6414-9

21 January 2020

exact match

0 references

cites work

Three years of experience: the Italian registry and safety data update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

A controlled trial of natalizumab for relapsing multiple sclerosis.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432776

Progressive multifocal leucoencephalopathy with peripheral demyelinating neuropathy after autologous bone marrow transplantation for acute myeloblastic leukemia (FAB5)

22 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22289966

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22289966

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00415-012-6414-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

PubMed publication ID

22289966

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22289966%20AND%20SRC:MED&resulttype=core&format=json